Get in before this October IPO



Daily Market Alert



Friday, September 18, 2026 • Daily Market Alert

You are receiving this email because you are subscribed to Daily Market Alert,
a publication from Behind the Markets.
If you no longer wish to receive these sponsored emails, please unsubscribe
here
<[link removed]>
.




Sponsored Content




Dear Reader,



Anthropic — the maker of Claude AI — is going public.



In fact, reports say it's just days away now.



Perhaps as soon as October.



The value of the company has doubled since the announcement.



Many experts think Anthropic could be worth $3 trillion by IPO day.



Google, Amazon and Nvidia are all heavily invested in this IPO.



Even Microsoft, who used to be associated with OpenAI's ChatGPT, is invested
in Anthropic.



Goldman Sachs, Morgan Stanley and JPMorgan are tripping over each other to get
a private stake before the IPO.



Even whole countries are invested …



Including the United Arab Emirates, Singapore and Qatar.



That's because Anthropic is a rare breed … the rarest, in fact.



You see, venture capitalists call a private company worth over a $1 billion a
unicorn.



$10 billion and it's a decacorn.



$100 billion is a hectocorn.



But what do you call a private company worth over a trillion dollars?

<[link removed]>

Anthropic is there, right now.



The first of its kind.



It's worth more than every American airline — combined.



It's even bigger than the U.S. defense budget …

<[link removed]>

Anthropic's annualized revenue grew by 80 times in the first quarter.



They've already filed the paperwork for an IPO …



Some estimates say they are going public as early as October.



Most analysts agree, it's going to happen sometime this fall at worst.



Now, here's what's really exciting … <[link removed]>



You can get a stake in this company, right now.



Today.



Before it goes public.



And have an opportunity to cash in on day one of this IPO.
<[link removed]>



All the best,

<[link removed]>



Michael Robinson
Director of Tech Strategies
Weiss Ratings

Full Details > <[link removed]>

 


Additional Reading from Daily Market Alerts:

Strong Buy Stocks for Friday, September 18, 2026: Five Names Riding
Thursday's Analyst Upgrades

Five stocks stand out heading into Friday, September 18, 2026, each carrying
a bullish rating change issued on Thursday, September 17. The Federal Open
Market Committee held the federal funds target range at 3.50% to 3.75% at its
July 29 meeting, and the CME Group FedWatch tool still prices roughly an 80%
probability that policy rates hold steady through the balance of 2026.

The five ideas below span intermodal freight, packaged food, blood-management
devices, equipment rental, and precision-timing semiconductors. Editorial notes
only, not investment advice.

J.B. Hunt Transport Services (JBHT) – Citizens Turns Bullish on Intermodal
Freight

Intermodal and dedicated-fleet trucking operator J.B. Hunt Transport Services
was upgraded from Market Perform to Outperform on Thursday by Citizens. The
thesis focuses on intermodal volumes reaccelerating as trans-Pacific
rail-conversion trends firm, dedicated contract-services segment producing
durable margin expansion through fleet-utilization gains, and pricing power
holding on contract renewals as truckload capacity remains constrained.

Shares traded near $238.56 during Thursday's session, up about 0.77%, giving
J.B. Hunt a market capitalization near $22 billion. The 52-week range of
$130.12 to $299.76 shows the stock trading in the upper half of the year's
range after a strong summer recovery. The trailing price-to-earnings multiple
sits at 33.81, and the dividend yield sits near 1%.

Consensus reads buy on the broader panel. Twenty sell-side firms cover the
name with 12 bullish, seven neutral, and one bearish. The average price target
of $293.95 implies roughly 23% upside from Thursday's level, and the panel high
sits at $370.

Risks: The panel is not uniformly aligned. UBS's Thomas Wadewitz maintained
Neutral at $264 on September 17 (target trimmed from $291), and Baird's Daniel
Moore trimmed to $290 from $320 the same day while maintaining Outperform.
Intermodal-volume trajectory, dedicated-fleet margin durability, and
truckload-competition dynamics all remain factors to monitor.

Kraft Heinz (KHC) – RBC Initiates Contrarian Bullish

Packaged-food giant Kraft Heinz drew a fresh Outperform initiation on
Thursday from RBC Capital. The thesis focuses on planned corporate
simplification (a potential split of the Kraft and Heinz portfolios) unlocking
sum-of-the-parts value, category-specific pricing normalization stabilizing
volumes, and productivity-savings program funding renewed advertising
investment behind core brands.

Shares traded near $24.89 during Thursday's session, up about 0.63%, giving
Kraft Heinz a market capitalization near $30 billion. The 52-week range of
$21.04 to $28.09 shows the stock trading in the middle of the year's range. The
trailing price-to-earnings multiple reads negative at negative 8.70 on a
depressed earnings base tied to impairment charges, and the dividend yield sits
near 6%.

Consensus reads sell on the broader panel, making RBC's initiation a clear
outlier. Fourteen sell-side firms cover the name with zero bullish, 10 neutral,
and four bearish. The average price target of $23.64 sits below Thursday's
level, and the panel high sits at $28.

Risks: The panel remains cautious in aggregate. Evercore ISI Group's David
Palmer maintained In-Line at $23 on September 14 (target trimmed from $24), and
TD Cowen's Robert Moskow maintained Hold at $22 on August 6. Portfolio-split
execution, packaged-food volume trajectory, and private-label competitive
dynamics all remain factors to monitor.

Haemonetics (HAE) – Citigroup Turns Bullish on Blood-Management Franchise

Blood-management medical-device maker Haemonetics was upgraded from Neutral
to Buy on Thursday by Citigroup analyst Joanne Wuensch, who raised her price
target to $123 from $92. The thesis focuses on plasma-collection franchise
growth stabilizing as commercial-plasma-collector customer relationships reset,
hospital segment (interventional-technology portfolio) gaining traction on
Vascade and Vivasure product ramps, and margin expansion holding as
manufacturing productivity gains compound.

Shares traded near $108.87 during Thursday's session, up about 2.48% on the
upgrade catalyst, giving Haemonetics a market capitalization near $5 billion.
The 52-week range of $47.32 to $109.83 shows the stock trading near multi-year
highs. The trailing price-to-earnings multiple sits at 53.32.

Consensus reads strong buy on the broader panel. Nine sell-side firms cover
the name with eight bullish and one neutral. The average price target of
$103.22 sits roughly in line with Thursday's level, and Raymond James' Andrew
Cooper sits at the high at $125 with an Outperform rating on September 3.

Risks: Even a strong-buy consensus carries dispersion. Citigroup's own prior
Neutral stance held from February at $75 (later $64 and $70), and the
plasma-collection segment remains exposed to commercial-collector customer
concentration. Interventional-technology adoption pace, plasma-franchise
stabilization, and margin-expansion trends all remain factors to monitor.

Continue Reading →
<[link removed]>


11780 US Highway 1,
Palm Beach Gardens, FL 33408-3080

Copyright © 2026 Weiss Ratings. All rights reserved.



At Daily Market Alert <[link removed]>,
our priority is delivering insightful perspectives on the financial landscape
straight to our audience.The content above is an important message from one of
our highly valued sponsors.






This email is sent on behalf of Daily Market Alert, a Behind the Markets LLC
("the Company") publication, including its managers, employees, and assigns.
The Company does not provide any guarantee or warranty regarding the accuracy
or reliability of the information advertised herein.

The Company is not affiliated with any specific security mentioned in this
email, nor does it receive compensation from any such entity

Please be advised that the Company is not registered or licensed by any
governing body in any jurisdiction to offer investment advice or
recommendations.

None of the content in this email should be construed as personalized
financial advice. Any investment decisions made based on the information
provided should be done so only after consulting with a qualified investment
advisor and conducting a thorough review of the relevant prospectus or
financial statements

You are receiving this because you signed up for the Daily Market Alert
newsletter.

Daily Market Alert is a Behind the Markets <[link removed]>
Publication.

Behind the Markets, LLC

4260 NW 1st Ave #55, Boca Raton, FL.

Unsubscribe
<[link removed]>
Terms of Use <[link removed]> Privacy Policy
<[link removed]>